Switch theme
Sign up to access all valuation multiples
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
2000
222
LTM Revenue $49.1M
LTM EBITDA -$64.7M
$35.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cellectis has a last 12-month revenue of $49.1M and a last 12-month EBITDA of -$64.7M.
In the most recent fiscal year, Cellectis achieved revenue of $44.6M and an EBITDA of -$10.2M.
Cellectis expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cellectis valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.8M | $44.6M | XXX | XXX | XXX |
| Gross Profit | $18.7M | $19K | XXX | XXX | XXX |
| Gross Margin | 2305% | 0% | XXX | XXX | XXX |
| EBITDA | -$99.5M | -$10.2M | XXX | XXX | XXX |
| EBITDA Margin | -12270% | -23% | XXX | XXX | XXX |
| Net Profit | -$114M | -$109M | XXX | XXX | XXX |
| Net Margin | -14058% | -243% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Cellectis's stock price is EUR 2 (or $2).
Cellectis has current market cap of EUR 182M (or $195M), and EV of EUR 33.0M (or $35.5M).
See Cellectis trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $35.5M | $195M | XXX | XXX | XXX | XXX | $-0.41 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Cellectis has market cap of $195M and EV of $35.5M.
Cellectis's trades at 0.7x LTM EV/Revenue multiple, and -0.5x LTM EBITDA.
Analysts estimate Cellectis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Cellectis and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $35.5M | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | -3.5x | XXX | XXX | XXX |
| P/E | -4.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 1.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCellectis's NTM/LTM revenue growth is 9%
Cellectis's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.5M for the same period.
Over next 12 months, Cellectis's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Cellectis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Cellectis and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 5397% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -23% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -90% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -13% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 42% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 218% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 243% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cellectis acquired XXX companies to date.
Last acquisition by Cellectis was XXXXXXXX, XXXXX XXXXX XXXXXX . Cellectis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Cellectis founded? | Cellectis was founded in 2000. |
| Where is Cellectis headquartered? | Cellectis is headquartered in France. |
| How many employees does Cellectis have? | As of today, Cellectis has 222 employees. |
| Who is the CEO of Cellectis? | Cellectis's CEO is Dr. Andre Choulika, PhD. |
| Is Cellectis publicy listed? | Yes, Cellectis is a public company listed on PAR. |
| What is the stock symbol of Cellectis? | Cellectis trades under ALCLS ticker. |
| When did Cellectis go public? | Cellectis went public in 2007. |
| Who are competitors of Cellectis? | Similar companies to Cellectis include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Cellectis? | Cellectis's current market cap is $195M |
| What is the current revenue of Cellectis? | Cellectis's last 12-month revenue is $49.1M. |
| What is the current EBITDA of Cellectis? | Cellectis's last 12-month EBITDA is -$64.7M. |
| What is the current EV/Revenue multiple of Cellectis? | Current revenue multiple of Cellectis is 0.7x. |
| What is the current EV/EBITDA multiple of Cellectis? | Current EBITDA multiple of Cellectis is -0.5x. |
| What is the current revenue growth of Cellectis? | Cellectis revenue growth between 2023 and 2024 was 5397%. |
| Is Cellectis profitable? | Yes, Cellectis is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
